Αποτελέσματα Αναζήτησης
Established in 2002, MedImmune Ventures was a Maryland-based venture capital investment arm of AstraZeneca PLC, a biopharmaceutical research and manufacturing company. The firm focused on investments in life science and biotech companies across the United States, Western Europe and Australia.
MedImmune Ventures was the corporate venture arm of MedImmune. The firm used to invest in private companies which develops small and large molecules, vaccines, pharmaceutical technologies and platforms.
28 Φεβ 2018 · AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.
MedImmune Ventures, a wholly-owned venture capital fund within the AstraZeneca Group, invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms.
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. [1] [2] MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. [3]
MedImmune Ventures invests in early to late stage, public and private biotechnology companies.
AstraZeneca, one of the world's leading pharmaceutical companies, announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million.
